Oxaliplatin liposomal - Mebiopharm

Drug Profile

Oxaliplatin liposomal - Mebiopharm

Alternative Names: L-OHP; MBP-426

Latest Information Update: 28 Oct 2016

Price : $50

At a glance

  • Originator Mebiopharm
  • Class Antineoplastics; Platinum complexes; Small molecules
  • Mechanism of Action DNA cross linking agents; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Adenocarcinoma

Most Recent Events

  • 21 Oct 2016 Phase-II clinical trials in Adenocarcinoma (of gastric and gastroesophageal junction) (Combination therapy, Second-line therapy) in USA (IV) (Mebiopharm pipeline, October 2016)
  • 07 Jun 2013 Biomarkers information updated
  • 01 Feb 2011 Mebiopharm completes enrolment in its phase I/II trial in Adenocarcinoma in USA (NCT00964080)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top